Target

MAPK

2 products, 2 indications

Indications

KRAS G12C-mutated solid tumors (1 products)

RAS or RAF mutated solid tumors (1 products)

1 drug

7 abstracts

Abstract

Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial design.

Org: Spanish National Cancer Research Center (CNIO), Barcelona Translational Genomics and Targeted Therapeutics in Solid Tumors Group,

Abstract

Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.

Org: Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, London, United Kingdom, The Institute of Cancer Research, London, United Kingdom, The Institue of Cancer Research, London, United Kingdom, The Institute of Cancer Research, Sutton, United Kingdom,

Abstract

Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.

Org: The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Trinity Health IHA Medical Group,

Abstract

Characterizing the tumor and immune landscape of patients with melanoma treated with combined checkpoint blockade and MAPK-targeted therapy.

Org: Division of Oncology, Rambam health care, Haifa, Israel, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel,

Abstract

Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.

Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Maryland Capital Region, Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Kansas Cancer Center, Kansas City, KS,

Abstract

Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions.

Org: Memorial Sloan Kettering Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CHUM,

Drug

olomorasib

Abstract

Deep multi-omic analyses to identify targetable pathways in desmoplastic small round cell tumor (DSRCT) with opportunities for clinical intervention.

Org: OHSU Knight Cancer Institute, Portland, OR, Portland, OR, Oregon Health & Science University, Knight Cancer Institute,